Revelation Biosciences, Inc. (NASDAQ:REVB) Sees Significant Drop in Short Interest

Revelation Biosciences, Inc. (NASDAQ:REVB) was the target of a significant drop in short interest in the month of September. As of September 15th, there was short interest totaling 256 shares, a drop of 56.0% from the August 31st total of 582 shares. Based on an average daily volume of 14,833 shares, the short-interest ratio is presently 0.0 days. Currently, 0.0% of the company’s shares are short sold.

Institutional Investors Weigh In On Revelation Biosciences

A hedge fund recently raised its position in Revelation Biosciences stock. Sabby Management LLC lifted its position in shares of Revelation Biosciences, Inc. (NASDAQ:REVB) by 192.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 605,702 shares of the company’s stock after buying an additional 398,651 shares during the quarter. Revelation Biosciences makes up 0.7% of Sabby Management LLC’s holdings, making the stock its 8th largest holding. Sabby Management LLC owned about 8.78% of Revelation Biosciences worth $484,000 at the end of the most recent quarter. Institutional investors and hedge funds own 12.80% of the company’s stock.

Revelation Biosciences Price Performance

Shares of NASDAQ:REVB traded down $0.02 during trading on Monday, reaching $0.85. 33,088 shares of the company were exchanged, compared to its average volume of 252,186. The business’s fifty day simple moving average is $1.03 and its 200-day simple moving average is $1.08. Revelation Biosciences has a 12-month low of $0.83 and a 12-month high of $6.76. The firm has a market capitalization of $3.39 million, a PE ratio of -0.07 and a beta of -0.14.

Revelation Biosciences (NASDAQ:REVB) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.87) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.01. On average, sell-side analysts anticipate that Revelation Biosciences will post -5.18 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings downgraded Revelation Biosciences from a “sell (e+)” rating to a “sell (e)” rating in a research report on Tuesday, August 25th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Revelation Biosciences Company Profile

Revelation Biosciences, Inc is a clinical-stage biotechnology company focused on developing immunologic therapies for diseases with significant unmet medical needs. The company’s research is centered on therapeutics designed to stimulate or modulate the body’s innate immune system, the first line of defense against infection and other disease processes.

Its development pipeline has included REVTx-99, an investigational intranasal therapy based on a proprietary beta-glucan formulation. The candidate has been studied for its potential to help prevent or reduce the severity of respiratory viral infections and associated complications, including acute respiratory distress.